This federal contract award is for $24,940.00 and was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer of genomics and molecular biology services. The contract is a Firm Fixed Price Purchase Order to provide the NHLBI's Sickle Cell Branch with the Olink assay, which will be used to study the profiling of plasma proteins among individuals with sickle cell disease. The contract has no set-aside designation and is...
This $24,940 firm-fixed-price purchase order was awarded by the National Heart Lung and Blood Institute, a civilian agency, to Psomagen Inc., a for-profit manufacturer of genomic and molecular biology services. The contract is to provide the Olink Explore HT platform to support the Sickle Cell Branch's efforts to detect proteomic biomarkers in individuals with sickle cell disease. The award does not have a set-aside designation. Psomagen has previously received other federal contract awards...
This is a $24,940 firm-fixed-price purchase order awarded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to Psomagen Inc., a genomics and molecular biology services company, to provide products for proteomic analysis on sickle cell plasma as part of ongoing sickle cell research efforts. The contract has an ultimate completion date of December 5, 2025. Psomagen Inc. is a subsidiary of Macrogen, Inc. and a for-profit manufacturer of goods that...
This is a $24,940 firm fixed-price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer and genomics/molecular biology services company, for Olink proteomic assays to support the Laboratory of Sickle Cell Genetics and Pathophysiology's research on the relationship between the TTR V122I genetic mutation and its protein variant. The award is not associated with a set-aside program and has an ultimate...
This is a $24,940 firm-fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services, to Psomagen Inc., a for-profit manufacturer of goods. The contract is for high-throughput, sensitive, and specific protein quantification analysis to maintain the integrity of Batch 3 of sickle cell disease (SCD) patient samples for the NHLBI's Laboratory of Sickle Cell Genetics and Pathophysiology....
This is a $24,940.00 firm fixed-price purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Psomagen Inc., a for-profit manufacturer of goods. The contract is to provide products to the Sickle Cell Branch to support their effort to investigate plasma biomarkers for the diagnosis and treatment of sickle cell disease. Psomagen is a genomics and molecular biology services company based in Rockville, Maryland, and a subsidiary of Macrogen, Inc. The...
This is a federal purchase order contract awarded by the National Heart, Lung and Blood Institute (NHLBI), a civilian agency under the National Institutes of Health (NIH), to Psomagen Inc., a genomics and molecular biology services company. The contract, valued at $15,344.80, is for Psomagen to provide OLINK EXPLORE HT (partial panel use) services to support next-generation sequencing-based proteomics analysis of plasma samples from hospitalized sepsis patients. The contract is not associated...
This is a $53,578 firm fixed-price purchase order awarded by the National Heart, Lung and Blood Institute (NHLBI) to Psomagen Inc., a subsidiary of Macrogen, Inc. The contract is for Psomagen to provide Multiplex Olink Proteomics Assays. This appears to be related to the NHLBI's Trans-Omics for Precision Medicine (TOPMed) initiative, as Psomagen holds a $500 million single-award Indefinite Delivery Vehicle (IDV) contract with NHLBI to support that program. The contract does not have a...
The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. government, awarded a $229,104 firm fixed-price purchase order contract to Psomagen Inc., a for-profit organization and manufacturer of goods. The contract, which has no set-aside designation, is for investigating transthyretin (TTR) variants and their impact on sickle cell disease severity using Olink proteomics technology. This contract is part of a larger $500 million single-award Indefinite Delivery...
This firm-fixed-price purchase order was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the National Institutes of Health (NIH), to Psomagen Inc., a for-profit organization and manufacturer of goods. The $23,030 contract is for OLINK HT ANALYSIS services, which likely refers to genomic sequencing and analysis capabilities provided by Psomagen. The contract has an ultimate completion date of July 29, 2025 and was awarded on July 30, 2024...